Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade

por Frankiw, Luke, Singh, Arun, Peters, Cole, Comin-Anduix, Begoña, Berent-Maoz, Beata, Macabali, Mignonette, Shammaie, Kiana, Quiros, Crystal, Kaplan-Lefko, Paula, Baselga Carretero, Ignacio, Ribas, Antoni, Nowicki, Theodore Scott
Publicado 2023

A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer

por Nguyen, Vina P., Campbell, Katie M., Nowicki, Theodore S., Elumalai, Nila, Medina, Egmidio, Baselga-Carretero, Ignacio, DiNome, Maggie L., Chang, Helena R., Oseguera, Denise K., Ribas, Antoni, Glaspy, John A.
Publicado 2023

Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade

por Abril-Rodriguez, Gabriel, Torrejon, Davis Y., Karin, Daniel, Campbell, Katie M., Medina, Egmidio, Saco, Justin D., Galvez, Mildred, Champhekar, Ameya S., Perez-Garcilazo, Ivan, Baselga-Carretero, Ignacio, Singh, Jas, Comin-Anduix, Begoña, Puig-Saus, Cristina, Ribas, Antoni
Publicado 2022